On Monday, Shares of Sprint Corporation (NYSE:S), lost -2.12% to $4.61.
Sprint Corporation continues its nationwide rollout of the innovative Direct 2 You service, which brings wireless sales, consultation and customer service directly to customers virtually whenever and wherever they want − for freei.Through Direct 2 You, a Sprint expert will set up a new Sprint mobile device, transfer all content, and demonstrate useful features.
Direct 2 You is now accessible in 20 metro areas, counting:
- Orlando metro area – Orlando, St. Cloud, Kissimmee
- Louis metro area – St. Louis, Mo.; Chesterfield, Mo.; O’Fallon, Mo.; St. Charles, Mo.; St. Louis, Ill.; Belleville, Ill.
- Minneapolis metro area – Minneapolis, St. Paul
- Phoenix metro area – Phoenix, Glendale, Scottsdale, Tempe, Mesa, Chandler, Gilbert, Peoria, Surprise
- San Antonio metro area – San Antonio, New Braunfels
- Seattle metro area – Seattle, Tacoma, Bellevue, Everett, Kent, Renton
Sprint Corporation, through its auxiliaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. Virgin Islands.
Shares of The Charles Schwab Corporation (NYSE:SCHW), declined -4.46% to $29.55, during its last trading session.
Charles Schwab & Co. has been fined $2 million for capital deficiencies and related supervisory failures, the Financial Industry Regulatory Authority said Monday, according to Market Watch.
Finra found that on three occasions between May 15 and July 1 last year, Schwab was net capital deficient by up to $775 million because the company had cash inflows that exceeded the amounts it could invest with existing facilities. As a result, Schwab transferred $1 billion to its parent company for overnight investment, which the company’s Treasury group approved as an unsecured loan under a revolving loa contract, according to Finra. Market Watch Reports
The Charles Schwab Corporation, through its auxiliaries, provides wealth administration, securities brokerage, banking, money administration, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services.
Finally, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), ended its last trade with -9.10% loss, and closed at $93.51.
Ultragenyx Pharmaceutical stated its financial results and corporate update for the quarter ended June 30, 2015.
Second Quarter 2015 Financial Results
For the second quarter of 2015, Ultragenyx stated a net loss attributable to common stockholders of $29.8 million, or $0.83 per share, basic and diluted, contrast with a net loss attributable to common stockholders for the second quarter of 2014 of $13.6 million, or $0.45 per share, basic and diluted. For the six months ended June 30, 2015, net loss attributable to common stockholders was $51.2 million, or $1.46 per share, basic and diluted, contrast with a net loss attributable to common stockholders for the same period in 2014 of $32.0 million, or $1.25 per share, basic and diluted. Net loss attributable to common stockholders differs from net loss due to dividends and other charges related to outstanding preferred stock, which was converted into common stock upon the company’s initial public offering.
Total operating expenses for the second quarter of 2015 were $30.1 million contrast with $13.7 million for the same period in 2014. Non-cash stock-based compensation accounted for $5.1 million and $0.9 million of total operating expenses in the second quarter of 2015 and 2014, respectively. Total operating expenses for the six months ended June 30, 2015 were $51.6 million contrast with $24.0 million for the same period in 2014. Non-cash stock-based compensation accounted for $7.5 million and $1.7 million of total operating expenses in the first half of 2015 and 2014, respectively. The enhance in total operating expenses is due to the enhance in clinical trial, manufacturing, other development activities, and supportive general and administrative costs as the company’s pipeline continues to advance to the late stages of development.
Cash, cash equivalents, and short-term investments were $326.0 million as of June 30, 2015. Subsequent to the end of the quarter, the company accomplished a public offering of 2,530,000 shares of common stock at a price to the public of $120.00 per share, which comprises the exercise in full by the underwriters of their option to purchase 330,000 additional shares of common stock. Net proceeds to Ultragenyx from the offering were about $286.6 million.
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
